PTC Therapeutics Inc (STU:BH3)
€ 36.8 0 (0%) Market Cap: 2.89 Bil Enterprise Value: 2.25 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 66/100

PTC Therapeutics Inc at UBS Global Healthcare Virtual Conference Transcript

May 26, 2021 / 04:00PM GMT
Release Date Price: €32.6 (+2.52%)
Colin Nigel Bristow
UBS Investment Bank, Research Division - Analyst

Good morning or good afternoon, I guess, and thank you, everyone, for joining the virtual UBS Global Healthcare Conference. I'm Colin Bristow. I'm one of the biotech analyst here at UBS.

It's my pleasure to have PTC Therapeutics here with us today. Speaking on behalf of the company, we have Matt Klein, Chief Development Officer; Eric Pauwels, Chief Business Officer; and Kylie O'Keefe, SVP, Head of Global Commercial and Corporate Strategy. So thank you all for joining us today.

Before we start, if anyone has a question, there is a question functionality in this global meet system. But alternatively, feel free to e-mail me at [email protected], and I can field the question for you.

So with that, I'll hand it over to Matt. Matt, over to you. Thanks.

Matthew B. Klein
PTC Therapeutics, Inc. - Chief Development Officer

Thank you, Colin. Let me start with a brief introduction to PTC. For those of you who don't know PTC, we are global commercial diversified

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot